首页> 美国卫生研究院文献>Journal of Korean Medical Science >Current Status of Molecular Diagnosis of Hereditary Hemolytic Anemia in Korea
【2h】

Current Status of Molecular Diagnosis of Hereditary Hemolytic Anemia in Korea

机译:韩国遗传性溶血性贫血的分子诊断现状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hereditary hemolytic anemia (HHA) is considered a group of rare hematological diseases in Korea, primarily because of its unique ethnic characteristics and diagnostic challenges. Recently, the prevalence of HHA has increased in Korea, reflecting the increasing number of international marriages and increased awareness of the disease. In particular, the diagnosis of red blood cell (RBC) enzymopathy experienced a resurgence, given the advances in diagnostic techniques. In 2007, the RBC Disorder Working Party of the Korean Society of Hematology developed the Korean Standard Operating Procedure for the Diagnosis of Hereditary Hemolytic Anemia, which has been continuously updated since then. The latest Korean clinical practice guidelines for diagnosing HHA recommends performing next-generation sequencing as a preliminary step before analyzing RBC membrane proteins and enzymes. Recent breakthroughs in molecular genetic testing methods, particularly next-generation sequencing, are proving critical in identifying and providing insight into cases of HHA with previously unknown diagnoses. These innovative molecular genetic testing methods have now become important tools for the management and care planning of patients with HHA. This review aims to provide a comprehensive overview of recent advances in molecular genetic testing for the diagnosis of HHA, with particular emphasis on the Korean context.
机译:遗传性溶血性贫血 (HHA) 在韩国被认为是一组罕见的血液病,主要是因为它独特的种族特征和诊断挑战。最近,HHA 的患病率在韩国有所增加,这反映了国际婚姻数量的增加和对该疾病的认识不断提高。特别是,鉴于诊断技术的进步,红细胞 (RBC) 酶病的诊断经历了复苏。2007 年,大韩血液学会红细胞疾病工作组制定了韩国遗传性溶血性贫血诊断标准操作程序,此后不断更新。韩国最新的 HHA 诊断临床实践指南建议在分析 RBC 膜蛋白和酶之前进行下一代测序作为初步步骤。分子遗传学检测方法的最新突破,特别是下一代测序,被证明对于识别和深入了解以前未知诊断的 HHA 病例至关重要。这些创新的分子遗传学检测方法现在已成为 HHA 患者管理和护理计划的重要工具。本综述旨在全面概述用于诊断 HHA 的分子遗传学检测的最新进展,特别强调韩国的情况。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号